DOP2010000251A - Paramyxovirus eficaz como antitumoral - Google Patents

Paramyxovirus eficaz como antitumoral

Info

Publication number
DOP2010000251A
DOP2010000251A DO2010000251A DO2010000251A DOP2010000251A DO P2010000251 A DOP2010000251 A DO P2010000251A DO 2010000251 A DO2010000251 A DO 2010000251A DO 2010000251 A DO2010000251 A DO 2010000251A DO P2010000251 A DOP2010000251 A DO P2010000251A
Authority
DO
Dominican Republic
Prior art keywords
virus
paramyxovirus
kill
antitumoral
effective
Prior art date
Application number
DO2010000251A
Other languages
English (en)
Inventor
Rudolf Beier
Florian Puhler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP2010000251A publication Critical patent/DOP2010000251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapuera y virus Fer-de-Lance, los cuales pueden ser usados para la producción de un medicamento para eI tratamiento de tumores. El virus tiene una selectividad para matar células tumorales humanas pero no para matar células diferenciadas normales humanas o en proliferación normal humanas con la misma dosis. Por medio de ingeniería genética, el virus se puede modificar de modo tal que se agreguen o reemplacen uno o más genes por los genes homólogos de un paramyxovirus relacionado. Por ese método, la actividad antitumoral del virus quimérico resultante se potencia en comparación con el virus parental.
DO2010000251A 2008-02-14 2010-08-13 Paramyxovirus eficaz como antitumoral DOP2010000251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
DOP2010000251A true DOP2010000251A (es) 2010-08-31

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000251A DOP2010000251A (es) 2008-02-14 2010-08-13 Paramyxovirus eficaz como antitumoral

Country Status (17)

Country Link
US (1) US20090208495A1 (es)
EP (1) EP2252307A2 (es)
JP (1) JP2011512344A (es)
KR (1) KR20100122482A (es)
CN (1) CN101945660A (es)
AU (1) AU2009214066A1 (es)
BR (1) BRPI0908365A2 (es)
CA (1) CA2715136A1 (es)
CO (1) CO6290694A2 (es)
CR (1) CR11631A (es)
DO (1) DOP2010000251A (es)
EA (1) EA201001266A1 (es)
EC (1) ECSP10010401A (es)
IL (1) IL206860A0 (es)
MX (1) MX2010008942A (es)
WO (1) WO2009101149A2 (es)
ZA (1) ZA201006561B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3210622T (pt) * 2009-08-21 2021-03-03 Univ Georgia Vacina recombinante contra o paramixovírus aviário e método de preparação e utilização da mesma
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
ES2492691T3 (es) * 2010-06-10 2014-09-10 Intervet International B.V. Composición antitumoral
US9505807B2 (en) 2012-01-24 2016-11-29 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
HRP20220653T1 (hr) * 2013-09-03 2022-06-24 Medimmune Limited Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US20200297787A1 (en) * 2018-07-13 2020-09-24 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CN101056646A (zh) * 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒

Also Published As

Publication number Publication date
IL206860A0 (en) 2010-12-30
JP2011512344A (ja) 2011-04-21
WO2009101149A2 (en) 2009-08-20
CR11631A (es) 2010-10-05
EA201001266A1 (ru) 2011-04-29
BRPI0908365A2 (pt) 2015-08-11
EP2252307A2 (en) 2010-11-24
US20090208495A1 (en) 2009-08-20
KR20100122482A (ko) 2010-11-22
CN101945660A (zh) 2011-01-12
ECSP10010401A (es) 2010-09-30
ZA201006561B (en) 2012-02-29
WO2009101149A3 (en) 2009-11-05
CO6290694A2 (es) 2011-06-20
AU2009214066A1 (en) 2009-08-20
MX2010008942A (es) 2010-09-07
CA2715136A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
DOP2010000251A (es) Paramyxovirus eficaz como antitumoral
BR112017017810A2 (pt) materiais e métodos para tratamento de hemoglobinopatias
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CY1122275T1 (el) Μεσεγχυματικα στρωματικα κυτταρα και χρησεις που σχετιζονται με αυτα
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
CU20140139A7 (es) Compuestos y composiciones para modular la actividad de egfr
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
CO7230336A2 (es) Inhibidores de indazol de la ruta de señalización de wnt y usos terapeúticos de los mismos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
EA201590888A1 (ru) Мутации флавивирусного белка оболочки, нарушающие разборку вириона
EA201391492A1 (ru) Соединения на основе микрорнк и способы модулирования активности mir-21
ECSP12011637A (es) Polipéptidos del factor ix modificados y usos de los mismos
EA201590747A1 (ru) Способы лечения с использованием аденовируса
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
EA201590782A1 (ru) Оксирановые амины
RU2014145910A (ru) Способы воздействия на экспрессию гена APOE
RU2014148877A (ru) Способы воздействия на экспрессию гена BRCA1
RU2014142752A (ru) Способы воздействия на экспрессию гена лактазы
RU2014146616A (ru) Способы воздействия на экспрессию гена SNRPN
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators